acut
respiratori
tract
infect
lead
caus
hospit
infant
young
children
develop
countri
major
determin
death
develop
countri
lower
respiratori
tract
infect
account
approxim
million
death
worldwid
death
year
therefor
huge
need
new
diagnost
tool
enabl
detect
broad
rang
respiratori
pathogen
especi
difficult
imposs
obtain
convent
cultur
method
recent
emerg
reemerg
differ
viral
threat
addit
reason
develop
accur
diagnost
method
allow
detect
caus
agent
exampl
sar
coronaviru
respons
epidem
countri
five
contin
influenza
first
emerg
hong
kong
caus
offici
human
infect
worldwid
year
approxim
fatal
current
influenza
pandem
aros
april
mexico
alreadi
kill
least
peopl
usa
alon
besid
emerg
agent
mani
new
virus
identifi
signific
respiratori
pathogen
recent
year
molecular
method
import
take
account
diagnost
algorithm
includ
human
metapneumovirus
new
human
coronaviru
human
bocaviru
novel
polyomaviru
wu
develop
nucleic
acid
screen
human
sampl
patient
infect
unknown
origin
new
respiratori
agent
probabl
ad
list
futur
year
collater
consequ
current
influenza
pandem
also
emphas
difficulti
diagnosi
influenza
basi
clinic
symptom
alon
necess
propos
altern
identif
search
influenza
viru
neg
least
sever
clinic
case
molecular
theranost
infecti
diseas
emerg
concept
molecular
microbiolog
tool
need
provid
accur
inform
data
thu
enabl
better
therapeut
intervent
field
respiratori
infect
avail
rapid
inform
regard
put
agent
would
two
import
consequ
first
differenti
viral
bacteri
pneumonia
often
difficult
especi
atyp
bacteria
involv
includ
mycoplasma
pneumonia
chlamydophila
pneumonia
even
legionella
speci
rapid
identif
agent
would
allow
adequ
use
antibiot
sinc
macrolid
quinolon
tetracyclin
indic
case
atyp
wherea
antibiot
indic
viral
pneumonia
thu
save
resist
reduc
cost
second
avail
antivir
drug
activ
influenza
virus
especi
initi
phase
infect
make
rapid
confirm
influenza
use
order
decid
whether
continu
antivir
treatment
convent
microbiolog
test
includ
bacteri
cultur
cell
cultur
virus
rapid
detect
bacteri
antigen
urin
streptococcu
pneumonia
legionella
pneumophila
serogroup
viral
antigen
respiratori
secret
use
immunofluoresc
enzymat
immunochromatograph
assay
serolog
test
use
target
specif
pathogen
subgroup
pathogen
conveni
use
either
clinician
microbiologist
diagnosi
must
broaden
larg
number
pathogen
addit
mani
virus
includ
recent
describ
one
list
earlier
poorli
detect
convent
test
molecular
tool
develop
extens
past
year
diagnosi
respiratori
infect
includ
inhous
commerci
test
excel
recent
review
avail
topic
regard
either
virus
virus
atyp
bacteria
addit
test
target
singl
pathogen
small
group
pathogen
influenza
virus
rhinoenterovirus
atyp
bacteria
concept
multiplex
pcr
assay
recent
emerg
enabl
simultan
detect
wide
rang
viral
bacteri
agent
involv
respiratori
infect
multiplex
approach
propos
year
ago
initi
lack
sensit
comparison
monoplex
techniqu
use
multipl
pcr
tube
may
circumv
lack
sensit
altern
strategi
minim
competit
probe
develop
allow
mixtur
primer
pair
reaction
tube
without
loss
sensit
current
avail
test
commerci
sourc
us
fda
ce
approv
allow
simultan
detect
pathogen
includ
virus
bacteria
follow
amplif
step
differ
strategi
use
detect
pcr
product
fragment
analysi
capillari
electrophoresi
probe
differ
size
fluid
microbeadbas
assay
hybrid
line
blot
microarray
number
rang
select
pathogen
differ
one
techniqu
anoth
may
evolv
time
need
investig
addit
pathogen
main
virus
target
techniqu
influenza
virus
includ
pandem
strain
human
respiratori
syncyti
virus
human
pneumovirus
parainfluenza
virus
human
coronovirus
includ
sarscov
human
rhinovirus
b
c
human
enterovirus
speci
human
respiratori
adenovirus
human
bocavirus
novel
wu
polyomaviru
regard
bacteria
assay
includ
cultur
microorgan
eg
staphylococcu
aureu
pneumonia
streptococcu
pyogen
moraxella
catarrhali
haemophilu
influenza
klebsiella
pneumonia
other
target
non
fastidiousgrow
agent
pneumonia
c
pneumonia
legionella
speci
bordetella
pertussi
mycobacterium
tuberculosi
clinic
point
view
multipl
pcr
assay
offer
mani
interest
featur
allow
correct
use
antimicrobi
drug
includ
antibiot
antiinfluenza
agent
detail
earlier
permit
set
rapid
isol
measur
prevent
nosocomi
spread
infect
cost
benefici
sinc
contribut
reduc
durat
hospit
stay
allow
diagnosi
dual
even
tripl
infect
clinic
sampl
use
test
consequ
sever
diseas
therapeut
strategi
bring
epidemiolog
result
use
evalu
season
circul
pathogen
even
patient
benefit
test
addit
diagnost
procedur
greatli
simplifi
sinc
test
perform
respiratori
sampl
singl
laboratori
result
avail
time
allow
earli
reevalu
clinic
decis
antiinfecti
treatment
isol
procedur
addit
benefit
patient
global
assess
shown
effici
term
money
save
cad
per
child
despit
rel
high
individu
cost
cad
test
comparison
convent
one
main
constraint
multiplex
pcr
assay
high
technolog
test
need
sever
hour
intens
laboratori
work
gener
result
case
sampl
treat
individu
result
usual
given
clinician
day
recept
sampl
requir
onset
empir
treatment
meantim
avail
result
also
mean
test
could
perform
emerg
condit
train
technician
present
h
day
day
week
anoth
difficulti
rais
interpret
result
wherea
convent
method
monoplex
molecular
techniqu
limit
mani
neg
result
pcr
multiplex
assay
shown
exhibit
import
rang
posit
result
difficulti
recogn
agent
caus
clinic
disord
whether
associ
may
play
role
sever
diseas
mention
earlier
role
coinfect
evalu
light
new
diagnost
tool
final
contrast
realtim
pcr
techniqu
quantit
persist
residu
genom
despit
absenc
replic
activ
may
sourc
mislead
interpret
despit
limit
routin
implement
new
tool
diagnosi
sever
acut
respiratori
infect
replac
convent
one
contribut
reevalu
clinic
data
light
list
firstlin
pathogen
whether
bacteria
virus
work
technic
feasibl
econom
justifi
contribut
build
new
algorithm
diagnosi
treatment
sever
respiratori
infect
